Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256419 | 0.85 | PSEN1 (0.52) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9226894 | 0.80 | NPBWR1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL19658952 | 0.79 | RIPK1 (0.56) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2271918 | 0.79 | PSEN1 (0.47) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20221921 | 0.78 | RIPK1 (0.45) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18366976 | 0.78 | RIPK1 (0.58) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21374341 | 0.78 | RIPK1 (0.47) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9282768 | 0.77 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL19659284 | 0.76 | RIPK1 (0.56) | RIPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2275154 | 0.74 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | RIPK1 3697/4885PSEN1 3/4885PSEN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.